Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a cyclin-dependent kinase inhibitor, ribociclib. With longer follow-up, it is clear that fulvestrant and ribociclib also prolong overall surviva...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 382; číslo 6; s. 514 - 524
Hlavní autoři: Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 06.02.2020
Témata:
Aged
Aminopyridines - administration & dosage
Aminopyridines - adverse effects
Aminopyridines/administration & dosage/adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Breast Neoplasms/drug therapy/mortality
Cancer therapies
Chemotherapy
Cyclin-dependent kinases
Drug Administration Schedule
Endocrine therapy
Epidermal growth factor
ErbB-2 protein
Female
Fulvestrant
Fulvestrant - administration & dosage
Fulvestrant - adverse effects
Fulvestrant/administration & dosage/adverse effects
Human health sciences
Humans
Hypotheses
Hypothesis testing
Kaplan-Meier Estimate
Middle Aged
Oncologie
oncology
Patients
Post-menopause
Postmenopause
Progression-Free Survival
Purines - administration & dosage
Purines - adverse effects
Purines/administration & dosage/adverse effects
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Sciences de la santé humaine
Statistical analysis
Survival
Targeted cancer therapy
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a cyclin-dependent kinase inhibitor, ribociclib. With longer follow-up, it is clear that fulvestrant and ribociclib also prolong overall survival.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
scopus-id:2-s2.0-85079075053
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1911149